Study Links a Novel Biomarker with Potential to Predict and Treat Skin Cancer Metastasis

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous squamous cell carcinoma (cSCC), the most common type of metastatic skin cancer. The new study opens in new tab/window's findings in The American Journal of Pathology opens in new tab/window, published by Elsevier, found that C5aR1 promotes the invasion of cSCC tumor cells. Its elevated presence suggests that C5aR1 might serve as a useful prognostic marker for metastatic disease and, potentially, a target for future therapies in advanced cSCC.

The incidence of cSCC is increasing. Exposure to solar UV radiation is the predominant risk factor for cSCC. Approximately 3% to 5% of primary cSCCs metastasize, and the prognosis for patients with metastatic cSCC is poor. Although most cases are curable by excision of the primary tumor, a subset of patients develop aggressive and metastatic disease with few treatment options. It is estimated that cSCC accounts for nearly 25% of annual skin cancer deaths.

Lead investigator Veli-Matti Kähäri, MD, PhD, Department of Dermatology, and FICAN West Cancer Research Laboratory University of Turku and Turku University Hospital, Turku, Finland, explains, "Currently, there are no established molecular markers in clinical practice for predicting the metastasis risk of primary cSCCs. There is an urgent need for predictive biomarkers for the prognosis of cSCC and for new therapeutic targets for metastatic cSCC."

Studies in multiple cancers have indicated that the complement system, which is a part of the human innate immune system and is a tumor-suppressing cytolytic mechanism, can also contribute to tumor progression and metastasis by inducing inflammation or causing immunosuppression. This prompted researchers conducting the current study to investigate the interaction between C5a (which acts as a signaling molecule in cancer) and its protein receptor C5aR1 (which is found on the surface of cells) in cSCC.

Investigators noted that when C5a binds to C5aR1, it activates signaling pathways within the cell, leading to changes in cell behavior. They examined C5aR1 in the context of cSCC progression and metastasis by combining in vitro 3D spheroid co-culture of cSCC cells and skin fibroblasts, human cSCC xenograft tumors grown in SCID (Severe Combined Immunodeficiency) mice, and a large panel of patient-derived tumor samples of non-metastatic cSCC, metastatic cSCCs and cSCC metastases.

First author Lauri Heiskanen, MD, Department of Dermatology, and FICAN West Cancer Research Laboratory University of Turku and Turku University Hospital, Turku, Finland, elaborates, "We observed that fibroblasts in the tumor microenvironment induced C5aR1 expression in cSCC cells. Exposure to recombinant C5a further increased the invasiveness of cSCC cells. In patient-derived cSCC samples, high C5aR1 expression — both in tumor cells and in stromal fibroblasts — was linked to metastasis risk and poor survival."

Researchers were surprised to find that fibroblasts influenced C5aR1 expression in cancer cells, and that the C5aR1 expression in stromal fibroblasts also had a role in metastasis and poor prognosis in cSCC. They also had not anticipated that C5aR1 expression would correlate with patient outcomes across a large clinical sample set.

Co-investigators Pilvi Riihilä, MD, PhD, and Liisa Nissinen, PhD, Department of Dermatology, and FICAN West Cancer Research Laboratory University of Turku and Turku University Hospital, Turku, Finland, conclude, "What is particularly interesting in the results of our study is how the tumor microenvironment — especially fibroblasts in this study — affects progression of cSCC through C5aR1. It emphasizes the idea that the interplay between tumor cells and stromal cells plays an important role in cancer progression. Our findings suggest that C5aR1 is a potential metastatic risk marker, a novel prognostic biomarker, and promising therapeutic target for cSCC."

Notes for editors

The article is “C5aR1 Promotes Invasion, Metastasis and Poor Prognosis in Cutaneous Squamous Cell Carcinoma,” by Lauri Heiskanen, Liisa Nissinen, Elina Siljamäki, Jaakko S. Knuutila, Teijo Pellinen, Markku Kallajoki, Jyrki Heino, Pilvi Riihilä, and Veli-Matti Kähäri (https://doi.org/10.1016/j.ajpath.2025.02.004 opens in new tab/window). It appears in The American Journal of Pathology, volume 195, issue 6 (June 2025), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(25)00073-2/fulltext opens in new tab/window.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors contact Veli-Matti Kähäri, MD, PhD, at [email protected] opens in new tab/window.

The study was supported by the Research Council of Finland, Sigrid Jusélius Foundation, Finnish Cancer Foundation, Cancer Foundation of Southwest Finland, Finnish Dermatological Society, Maud Kuistila Memorial Foundation, Ida Montin Foundation, Finnish Medical Foundation, Finnish Cultural Foundation, Paulo Foundation, Päivikki and Sakari Sohlberg Foundation, and the Turku University Hospital VTR grant.

About The American Journal of Pathology

The American Journal of Pathology opens in new tab/window, official journal of the American Society for Investigative Pathology opens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.org opens in new tab/window

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.